Annexon, Inc.
ANNX
$2.53
-$0.13-4.89%
| Weiss Ratings | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.92 | |||
| Price History | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.43% | |||
| 30-Day Total Return | -38.59% | |||
| 60-Day Total Return | -43.90% | |||
| 90-Day Total Return | -66.45% | |||
| Year to Date Total Return | -54.00% | |||
| 1-Year Total Return | -56.15% | |||
| 2-Year Total Return | -43.02% | |||
| 3-Year Total Return | -31.44% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -68.33% | |||
| 52-Week Low % Change | 15.65% | |||
| Price | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $8.40 | |||
| 52-Week Low Price | $2.30 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 27, 2024 | |||
| Valuation | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 291.83M | |||
| Enterprise Value | 8.78M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.01 | |||
| Earnings Per Share Growth | -43.21% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.99 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $2.53 | |||
| Enterprise Value/EBITDA (TTM) | -0.06 | |||
| Enterprise Value/EBIT | -0.06 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 147.81M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 822 5500 | |||
| Address | 1400 Sierra Point Parkway Brisbane, CA 94005 | |||
| Website | www.annexonbio.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -29.73% | |||
| Return on Equity | -- | |||
| Income Statement | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -151.92M | |||
| EBIT (TTM) | -154.07M | |||
| Net Income (TTM) | -138.20M | |||
| Net Income Avl. to Common (TTM) | -138.20M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -74.21% | |||
| EPS Diluted (TTM) | -1.01 | |||
| EPS Diluted Growth (Q YOY) | 7.82% | |||
| Balance Sheet | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 312.02M | |||
| Cash Per Share (Q) | $2.11 | |||
| Total Current Assets (Q) | 316.46M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 293.11M | |||
| Current Ratio (Q) | 10.372 | |||
| Book Value Per Share (Q) | $2.68 | |||
| Total Assets (Q) | 350.07M | |||
| Total Current Liabilities (Q) | 30.51M | |||
| Total Debt (Q) | 28.97M | |||
| Total Liabilities (Q) | 56.97M | |||
| Total Common Equity (Q) | 293.11M | |||
| Cash Flow | ANNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -218.80M | |||
| Cash from Financing (TTM) | 161.21M | |||
| Net Change in Cash (TTM) | -175.61M | |||
| Levered Free Cash Flow (TTM) | -62.80M | |||
| Cash from Operations (TTM) | -118.01M | |||
